HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ten Berge, R L Articles by Meijer, C J L M Search for Related Content PubMed PubMed Citation Articles by Ten Berge, R L Articles by Meijer, C J L M

MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form

¹ Department of Pathology, University Hospital Vrije Universiteit, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
² Department of Obstetrics and Gynaecology, University Hospital Vrije Universiteit
³ Department of Dermatology, University Hospital Vrije Universiteit
⁴ Department of Pathology, Rijnstate Hospital, 6815 AD Arnhem, The Netherlands
⁵ Biotech and Research Division, Sanbe Fama, Bandung, Indonesia

Dr ten Berge rl.tenberge{at}azvu.nl Aims—To investigate whether MUC1 mucin, a high molecular weight transmembrane glycoprotein, also known as epithelial membrane antigen (EMA), differs in its expression and degree of glycosylation between anaplastic large cell lymphoma (ALCL) and classic Hodgkin's disease (HD), and whether MUC1 immunostaining can be used to differentiate between CD30 positive large cell lymphomas.

Methods/Results—Using five different monoclonal antibodies (E29/anti-EMA, DF3, 139H2, VU-4H5, and SM3) that distinguish between various MUC1 glycoforms, high MUC1 expression (50–95% of tumour cells positive) was found in 13 of 17 anaplastic lymphoma kinase (ALK) positive systemic nodal ALCLs, and in one of 20 cases of classic HD. Scattered or focal staining (< 25% of tumour cells) was seen in two additional ALK positive systemic ALCLs, two additional classic HD cases, and in three of 20 cases of ALK negative systemic nodal ALCL. Primary cutaneous ALCL showed no staining with the anti-MUC1 antibodies. Antibodies detecting hypoglycosylated MUC1 were found to be absent in all lymphomas (SM3) or present in only six of 15 ALK positive ALCLs (VU-4H5).

Conclusions—MUC1 is preferentially expressed by a subtype of systemic nodal ALCL, characterised by ALK expression, but is found in only a few cases of classic HD and ALK negative ALCL. Therefore, although MUC1 could be used in a panel of markers for CD30 positive lymphomas, it is probably not a valuable tool to differentiate between ALK negative CD30 positive large cell lymphomas. Finally, the degree of MUC1 glycosylation in lymphomas is relatively high, compared with the aberrant hypoglycosylation found in adenocarcinomas.

Key Words: MUC1 (epithelial membrane antigen) glycoforms • anaplastic large cell lymphoma • ALK • Hodgkin's disease

This article has been cited by other articles:

				E. Jacobsen Anaplastic Large-Cell Lymphoma, T-/Null-Cell Type Oncologist, July 1, 2006; 11(7): 831 - 840. [Abstract] [Full Text] [PDF]

				J J Oudejans, R L ten Berge, and C J L M Meijer Immune escape mechanisms in ALCL J. Clin. Pathol., June 1, 2003; 56(6): 423 - 425. [Full Text] [PDF]

				G. Z. Rassidakis, A. Goy, L. J. Medeiros, Y. Jiang, A. Thomaides, Y. Remache, F. Cabanillas, A. H. Sarris, and F. Gilles Prognostic Significance of MUC-1 Expression in Systemic Anaplastic Large Cell Lymphoma Clin. Cancer Res., June 1, 2003; 9(6): 2213 - 2220. [Abstract] [Full Text] [PDF]